Xilio Therapeutics Inc (NASDAQ:XLO) does about 1.14M shares in volume on a normal day but saw 5429754 shares change hands in the recent trading day. The company now has a market cap of 36.25M USD. Its current market price is $0.70, marking a decrease of -34.57% compared to the previous close of $1.07. The 52 week high reached by this stock is $1.70 whilst the lowest price level in 52 weeks is $0.62. The script in recent trading has seen the stock touch a high of $7 and a low of $7.
1 analysts observing the Xilio Therapeutics Inc (XLO) stock have set the 12-month price targets for the company’s shares at between $7 and $7. The consensus objective for the share price is $4.00, suggesting that the stock has a potential upside of 82.5% over the period. The median price target is 90.0% away from the current levels at $7.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on December 21, 2022 when Chardan Capital Markets initiated the stock to “Buy” and issued a price target of $7. Raymond James initiated its price target at $31.
The current price level is -16.97%, -10.53%, and -21.18% away from its SMA20, SMA50, and SMA200 respectively, with the XLO price moving above the 50-day SMA on current market day. Xilio Therapeutics Inc (XLO) stock is down -20.79% over the week and -7.27% over the past month. Its price is -26.69% year-to-date and -25.20% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year. Expected sales for next quarter are $7.4M, which analysts say will come at $25.1M for the current fiscal year and next year at $25.6M. In addition, estimates put the company’s current quarterly revenue at an average of $7.4M.
Its 12-month price target is $7. To reach the target analysts have set, the stock logically needs to grow 82.5 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $7, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $7.
Outstanding shares total 51.78M with insiders holding 28.18% of the shares and institutional holders owning 40.58% of the company’s common stock. The company has a return on investment of -313.20% and return on equity of -297.84%. The beta has a value of 0.02. Price to book ratio is 3.39 and price to sales ratio is 3.91.
